PRISM BioLab and Receptor.AI Team Up on AI-Driven Small-Molecule Drug Discovery

PRISM BioLab Co. LTD ( (JP:206A) ) has shared an update.

PRISM BioLab and Receptor.AI have signed a drug discovery collaboration to build an integrated, AI-navigated, physics-guided platform for designing orally available small molecules against intracellular protein–protein interactions, membrane proteins, and complex receptor systems. The effort combines PRISM’s conformationally rigid PepMetics chemistry with Receptor.AI’s multi-objective AI navigation engine, initially targeting a receptor involved in metabolic disease, including obesity.

Under the agreement, Receptor.AI will use its design algorithms to explore PRISM’s specialized chemical space while both firms jointly seek pharmaceutical partners to apply the combined technologies. Beyond producing clinical candidates, the collaboration is intended to demonstrate the capabilities of this integrated platform, deepen specialized know-how, and position both companies for expanded partnering opportunities in AI-driven small-molecule drug discovery.

The most recent analyst rating on (JP:206A) stock is a Hold with a Yen191.00 price target. To see the full list of analyst forecasts on PRISM BioLab Co. LTD stock, see the JP:206A Stock Forecast page.

More about PRISM BioLab Co. LTD

PRISM BioLab Co., Ltd. is a drug discovery company that develops orally available small molecules targeting challenging protein–protein interactions and membrane proteins through its proprietary PepMetics technology and peptide-mimetic small-molecule library. Receptor.AI Inc. is a U.S.-based TechBio firm focused on preclinical drug discovery using a modular, generative AI ecosystem and physics-informed modeling, with existing collaborations with major Japanese pharmaceutical companies.

Average Trading Volume: 631,326

Technical Sentiment Signal: Buy

Current Market Cap: Yen7.53B

For an in-depth examination of 206A stock, go to TipRanks’ Overview page.